Carlsmed (NASDAQ:CARL) Stock Price Expected to Rise, BTIG Research Analyst Says

Carlsmed (NASDAQ:CARL) had its price target boosted by analysts at BTIG Research from $24.00 to $26.00 in a research report issued on Wednesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. BTIG Research‘s target price points to a potential upside of 76.75% from the company’s current price.

CARL has been the subject of several other reports. Needham & Company LLC upped their target price on shares of Carlsmed from $17.00 to $22.00 and gave the stock a “buy” rating in a research report on Wednesday. Wall Street Zen upgraded Carlsmed from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Truist Financial raised their price target on Carlsmed from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Carlsmed in a research note on Wednesday, November 4th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $21.25.

Carlsmed Trading Down 8.3%

Shares of Carlsmed stock opened at $14.71 on Wednesday. Carlsmed has a 1 year low of $8.50 and a 1 year high of $17.23. The firm has a market cap of $401.58 million, a PE ratio of -10.29 and a beta of 1.97. The company has a debt-to-equity ratio of 0.18, a current ratio of 8.84 and a quick ratio of 8.66. The company has a 50 day simple moving average of $14.87 and a two-hundred day simple moving average of $12.52.

Carlsmed (NASDAQ:CARL) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.08. The firm had revenue of $21.55 million for the quarter. Carlsmed had a negative net margin of 57.42% and a negative return on equity of 38.06%. Analysts expect that Carlsmed will post -1.50 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Carlsmed

A number of institutional investors have recently made changes to their positions in the business. Jupiter Topco LLC bought a new position in shares of Carlsmed during the 2nd quarter valued at $12,992,000. Janus Henderson Group PLC raised its position in Carlsmed by 7.6% in the 1st quarter. Janus Henderson Group PLC now owns 1,227,452 shares of the company’s stock worth $11,108,000 after purchasing an additional 86,834 shares during the period. Parkman Healthcare Partners LLC bought a new stake in Carlsmed in the second quarter worth $6,200,000. BlackRock Inc. bought a new stake in Carlsmed in the second quarter worth $5,528,000. Finally, Russell Investments Group Ltd. boosted its position in Carlsmed by 85.3% during the third quarter. Russell Investments Group Ltd. now owns 257,805 shares of the company’s stock valued at $3,627,000 after buying an additional 118,663 shares during the period.

Carlsmed Company Profile

Carlsmed, Inc. is a medical technology company focused on personalized solutions for spine surgery. The company combines patient-specific planning, advanced imaging, software and additive manufacturing to develop implants designed to address the anatomical needs of individual patients. Its products include the aprevo® patient-specific interbody implant system, which is designed for use in spinal fusion procedures. Carlsmed’s technology is intended to support surgeons in planning procedures and selecting or creating implants that may help restore spinal alignment and improve surgical precision.